重组人血管内皮抑制素联合顺铂治疗乳腺癌恶性胸腔积液疗效观察

Efficacy observation of recombinant human endostatin combined with cisplatin in the treatment of malignant pleural effusion in breast cancer

目的探究重组人血管内皮抑制素联合顺铂治疗乳腺癌恶性胸腔积液的疗效。方法经我院伦理委员会同意后,将46例乳腺癌合并恶性胸腔积液患者随机分为联合组和对照组各23例。联合组予以重组人血管内皮抑制素联合顺铂治疗,对照组予以顺铂治疗。比较两组患者疗效和副作用,观察治疗前后生活质量[功能状态(KPS)评分、体力状况(ZPS)评分]和血清肿瘤标记物[癌胚抗原(CEA)、糖类抗原125(CA125)、糖类抗原153(CA153)]水平变化。结果联合组治疗总有效率高于对照组(P<0.05)。治疗4周后,两组患者ZPS评分、血清CEA、CA125、CA153水平均较治疗前降低,KPS评分则升高,且联合组改善幅度高于对照组(P<0.05)。两组患者副作用比较差异不显著(P>0.05)。结论重组人血管内皮抑制素联合顺铂可有效改善乳腺癌合并恶性胸腔积液患者的临床症状和生活质量,降低肿瘤标记物水平,且不增加副作用。

Objective To investigate the efficacy of recombinant human endostatin combined with cisplatin in the treatment of malignant pleural effusion of breast cancer. Methods After the consent of the ethics committee of our hospital,46 patients with breast cancer and malignant pleural effusion were randomly divided into the combined group and the control group,23 cases in each group.The combined group was treated with recombinant human endostatin combined with cisplatin,while the control group was treated with cisplatin.The effects and side effects of the two groups were compared,and the quality of life [karnofsky performance status（KPS） score,physical status（ZPS） score] and serum tumor markers [carcinoembryonic antigen（CEA）,carbohydrate antigen 125（CA125）,carbohydrate antigen 153（CA153）] before and after treatment were observed. Results The total effective rate of the combined group was higher than that of the control group（P〈0.05）.After 4 weeks of treatment,the levels of ZPS scores,serum CEA,CA125 and CA153 in the two groups were lower than those before the treatment,and the KPS score increased,and the improvement of the combined group was higher than that of the control group（P〈0.05）.There was no significant difference in side effects between the two groups（P〉0.05）. Conclusion Recombinant human endostatin combined with cisplatin can effectively improve the clinical symptoms and quality of life of patients with breast cancer complicated with malignant pleural effusion,reduce the level of tumor markers,and do not increase side effects.